Felbaum DR, Maxwell C, Naydin S, et al. Carotid Stenosis: Utility of Diagnostic Angiography. World Neurosurg. 2019;121:e962-e966. doi:10.1016/j.wneu.2018.10.054.

Shulman DS, Klega K, Imamovic-Tuco A, et al. Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group. Br J Cancer. 2018;119(5):615-621. doi:10.1038/s41416-018-0212-9.

Leyton-Mange JS, Hucker WJ, Mihatov N, et al. Experience With Wearable Cardioverter-Defibrillators at 2 Academic Medical Centers. JACC Clin Electrophysiol. 2018;4(2):231-239. doi:10.1016/j.jacep.2017.09.180.

Capper D, Stichel D, Sahm F, et al. Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. Acta Neuropathol. 2018;136(2):181-210. doi:10.1007/s00401-018-1879-y.

Waszak SM, Northcott PA, Buchhalter I, et al. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol. 2018;19(6):785-798. doi:10.1016/S1470-2045(18)30242-0.

Živná M, Kidd K, Přistoupilová A, et al. Noninvasive Immunohistochemical Diagnosis and Novel Mutations Causing Autosomal Dominant Tubulointerstitial Kidney Disease. J Am Soc Nephrol. 2018;29(9):2418-2431. doi:10.1681/ASN.2018020180.

Renneville A, Boissel N, Nibourel O, et al. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Leukemia. 2012;26(6):1247-54. doi:10.1038/leu.2011.382.

Rosellini AJ, Liu H, Petukhova MV, et al. Recovery from DSM-IV post-traumatic stress disorder in the WHO World Mental Health surveys. Psychol Med. 2018;48(3):437-450. doi:10.1017/S0033291717001817.

Scott KM, Koenen KC, King A, et al. Post-traumatic stress disorder associated with sexual assault among women in the WHO World Mental Health Surveys. Psychol Med. 2018;48(1):155-167. doi:10.1017/S0033291717001593.

Hess GP, Natarajan P, Faridi KF, Fievitz A, Valsdottir L, Yeh RW. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing. Circulation. 2017;136(23):2210-2219. doi:10.1161/CIRCULATIONAHA.117.028430.